AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MRVI · NASDAQ · Biotechnology

Maravai LifeSciences (MRVI)

Supplies nucleic-acid tools and biologics testing products for therapies, vaccines, diagnostics, and research.

$7.46

After hours+0.01 (+0.13%)

At close$7.45(+3.91%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	67	74	64	73	65	56	47	47	42	50	66	51
Cost of revenue	37	35	38	38	37	37	39	40	36	38	32	31
Gross profit	30	39	26	35	28	19	8	8	6	12	34	21
	46	46	45	45	197	57	57	74	−110	19	31	36
Research & development	4	5	5	5	4	5	5	5	10	4	4	4
	39	38	41	41	39	41	40	39	78	15	27	32
General & administrative	0	0	0	0	0	0	0	0	0	0	0	32
Other expenses	2	3	−1	−1	154	11	12	31	−198	0	0	0
Operating income	−15	−7	−19	−10	−169	−38	−49	−66	115	−7	2	−15
	−5	663	−4	−7	−7	−8	−4	−8	−161	−56	−9	−7
Interest income	7	7	7	7	7	6	3	3	15	2	2	1
Interest expense	12	15	11	12	14	11	7	7	7	7	6	5
Other non-operating income	−6	−679	−7	−5	−7	−3	−3	1	154	50	3	2
Income before tax	−21	656	−22	−17	−176	−47	−53	−74	−45	−63	−7	−22
Income tax expense	−5	766	0	−2	0	0	0	−4	0	0	0	0
Net income from continuing operations	−15	−110	−23	−14	−176	−46	−53	−70	−45	−63	−6	−22
Net income	−6	−106	−12	−8	−99	−26	−30	−40	−26	−36	−4	−12
EPS, basic	−$0.05	−$0.80	−$0.09	−$0.06	−$0.70	−$0.18	−$0.21	−$0.27	−$0.18	−$0.25	−$0.03	−$0.08
EPS, diluted	−$0.05	−$0.80	−$0.09	−$0.06	−$0.70	−$0.18	−$0.21	−$0.27	−$0.18	−$0.25	−$0.03	−$0.08
Weighted average shares, basic	132	132	132	136	142	140	143	144	145	145	146	148
Weighted average shares, diluted	132	132	132	136	142	140	143	144	145	145	146	148
EBITDA	4	685	2	10	−148	−21	−31	−52	−22	−42	12	−5
Depreciation & amortization	13	13	14	15	14	15	15	15	16	15	13	12
EBIT	−9	672	−12	−5	−162	−35	−46	−67	−38	−56	−1	−17